BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rossi L, Martin B, Hortin G, White R, Foster M, Moharram R, Stroncek D, Wang E, Marincola F, Panelli M. Inflammatory protein profile during systemic high dose interleukin-2 administration. Proteomics 2006;6:709-20. [DOI: 10.1002/pmic.200500004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Loening SA, Jung K. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. Cancer Lett 2008;269:85-92. [PMID: 18504068 DOI: 10.1016/j.canlet.2008.04.022] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
2 Moschos SJ, Mandic M, Kirkwood JM, Storkus WJ, Lotze MT. Focus on FOCIS: interleukin 2 treatment associated autoimmunity. Clin Immunol 2008;127:123-9. [PMID: 18405863 DOI: 10.1016/j.clim.2008.02.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
3 Hortin GL, Jortani SA, Ritchie JC Jr, Valdes R Jr, Chan DW. Proteomics: a new diagnostic frontier. Clin Chem 2006;52:1218-22. [PMID: 16675505 DOI: 10.1373/clinchem.2006.067280] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 4.5] [Reference Citation Analysis]
4 Hegmans JP, Veltman JD, Fung ET, Verch T, Glover C, Zhang F, Allard WJ, T'Jampens D, Hoogsteden HC, Lambrecht BN, Aerts J. Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS. Technol Cancer Res Treat 2009;8:323-32. [PMID: 19754208 DOI: 10.1177/153303460900800502] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
5 Bouwhuis MG, Ten Hagen TL, Suciu S, Eggermont AM. Autoimmunity and treatment outcome in melanoma. Curr Opin Oncol 2011;23:170-6. [PMID: 21150603 DOI: 10.1097/CCO.0b013e328341edff] [Cited by in Crossref: 42] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
6 Sapan CV, Lundblad RL. Review of methods for determination of total protein and peptide concentration in biological samples. Prot Clin Appl 2015;9:268-76. [DOI: 10.1002/prca.201400088] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
7 Jin P, Wang E, Provenzano M, Deola S, Selleri S, Ren J, Voiculescu S, Stroncek D, Panelli MC, Marincola FM. Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets. J Transl Med 2006;4:26. [PMID: 16805915 DOI: 10.1186/1479-5876-4-26] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 1.8] [Reference Citation Analysis]
8 Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Thurin M, Trinchieri G, Wang E, Wigginton J, Chaussabel D, Coukos G, Dhodapkar M, Håkansson L, Janetzki S, Kleen TO, Kirkwood JM, Maccalli C, Maecker H, Maio M, Malyguine A, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S, Slingluff CL Jr, Stroncek DF, Streicher H, Wu X, Zeskind B, Zhao Y, Zocca MB, Zwierzina H, Marincola FM. A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med 2008;6:81. [PMID: 19105846 DOI: 10.1186/1479-5876-6-81] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
9 Walter M, Heinze C, Steiner T, Pilchowski R, von Eggeling F, Wunderlich H, Junker K. Immunochemotherapy-associated protein patterns in tumour tissue and serum of patients with metastatic renal cell carcinoma. Arch Physiol Biochem 2010;116:197-207. [PMID: 20836751 DOI: 10.3109/13813455.2010.513392] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Longobardi S, Gravagnuolo AM, Rea I, De Stefano L, Marino G, Giardina P. Hydrophobin-coated plates as matrix-assisted laser desorption/ionization sample support for peptide/protein analysis. Analytical Biochemistry 2014;449:9-16. [DOI: 10.1016/j.ab.2013.11.021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
11 Hortin GL, Remaley AT. Mass determination of major plasma proteins by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Proteom 2006;2:103-15. [DOI: 10.1385/cp:2:1:103] [Cited by in Crossref: 9] [Article Influence: 0.6] [Reference Citation Analysis]
12 Rossi L, Moharram R, Martin BM, White RL, Panelli MC. Detection of human MCP-4/CCL13 isoforms by SELDI immunoaffinity capture. J Transl Med 2006;4:5. [PMID: 16433902 DOI: 10.1186/1479-5876-4-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
13 Banks RE, Craven RA, Harnden P, Madaan S, Joyce A, Selby PJ. Key clinical issues in renal cancer: a challenge for proteomics. World J Urol 2007;25:537-56. [DOI: 10.1007/s00345-007-0199-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
14 Hu S, Loo JA, Wong DT. Human body fluid proteome analysis. Proteomics. 2006;6:6326-6353. [PMID: 17083142 DOI: 10.1002/pmic.200600284] [Cited by in Crossref: 359] [Cited by in F6Publishing: 325] [Article Influence: 23.9] [Reference Citation Analysis]
15 Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, Kim DW, Deraffele G, Pos Z, Marincola FM, Kaufman HL. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009;27:2645-52. [PMID: 19364969 DOI: 10.1200/JCO.2008.19.1106] [Cited by in Crossref: 130] [Cited by in F6Publishing: 65] [Article Influence: 10.0] [Reference Citation Analysis]
16 Ryberg H, An J, Darko S, Lustgarten JL, Jaffa M, Gopalakrishnan V, Lacomis D, Cudkowicz M, Bowser R. Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve 2010;42:104-11. [PMID: 20583124 DOI: 10.1002/mus.21683] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 6.3] [Reference Citation Analysis]
17 Wu DC, Wang KY, Wang SSW, Huang CM, Lee YW, Chen MI, Chuang SA, Chen SH, Lu YW, Lin CC, Lee KW, Hsu WH, Wu KP, Chen YJ. Exploring the expression bar code of SAA variants for gastric cancer detection. Proteomics. 2017;17. [PMID: 28493537 DOI: 10.1002/pmic.201600356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
18 Pakharukova NA, Pastushkova LK, Trifonova OP, Moshkovskii SA, Larina IM. Variability of low-molecular-weight serum subproteome in healthy humans under the conditions of normal vital activity. Hum Physiol 2011;37:193-9. [DOI: 10.1134/s0362119711020149] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
19 Malle E, Sodin-Semrl S, Kovacevic A. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 2009;66:9-26. [PMID: 18726069 DOI: 10.1007/s00018-008-8321-x] [Cited by in Crossref: 122] [Cited by in F6Publishing: 122] [Article Influence: 9.4] [Reference Citation Analysis]
20 Whistler T, Rollin D, Vernon SD. A method for improving SELDI-TOF mass spectrometry data quality. Proteome Sci 2007;5:14. [PMID: 17803814 DOI: 10.1186/1477-5956-5-14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
21 Weiss GR, Grosh WW, Chianese-Bullock KA, Zhao Y, Liu H, Slingluff CL Jr, Marincola FM, Wang E. Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res 2011;17:7440-50. [PMID: 21976537 DOI: 10.1158/1078-0432.CCR-11-1650] [Cited by in Crossref: 61] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
22 Hortin GL. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem. 2006;52:1223-1237. [PMID: 16644871 DOI: 10.1373/clinchem.2006.069252] [Cited by in Crossref: 264] [Cited by in F6Publishing: 243] [Article Influence: 16.5] [Reference Citation Analysis]
23 Flood-Nichols SK, Tinnemore D, Wingerd MA, Abu-Alya AI, Napolitano PG, Stallings JD, Ippolito DL. Longitudinal analysis of maternal plasma apolipoproteins in pregnancy: a targeted proteomics approach. Mol Cell Proteomics 2013;12:55-64. [PMID: 23059768 DOI: 10.1074/mcp.M112.018192] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
24 Findeisen P, Neumaier M. Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective. Clin Chem Lab Med 2009;47:666-84. [PMID: 19445650 DOI: 10.1515/CCLM.2009.159] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
25 Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman WH, Hirohashi Y, Imai K, Jacobson J, Jinushi M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen TO, Lehmann PV, Liotta L, Lotze MT, Maio M, Malyguine A, Masucci G, Matsubara H, Mayrand-Chung S, Nakamura K, Nishikawa H, Palucka AK, Petricoin EF, Pos Z, Ribas A, Rivoltini L, Sato N, Shiku H, Slingluff CL, Streicher H, Stroncek DF, Takeuchi H, Toyota M, Wada H, Wu X, Wulfkuhle J, Yaguchi T, Zeskind B, Zhao Y, Zocca MB, Marincola FM. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med 2009;7:45. [PMID: 19534815 DOI: 10.1186/1479-5876-7-45] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
26 Findeisen P, Neumaier M. Functional protease profiling for diagnosis of malignant disease. Proteomics Clin Appl 2012;6:60-78. [PMID: 22213637 DOI: 10.1002/prca.201100058] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
27 Molina S, Missé D, Roche S, Badiou S, Cristol J, Bonfils C, Dierick J, Veas F, Levayer T, Bonnefont-rousselot D, Maurel P, Coste J, Fournier-wirth C. Identification of apolipoprotein C-III as a potential plasmatic biomarker associated with the resolution of hepatitis C virus infection. Prot Clin Appl 2008;2:751-61. [DOI: 10.1002/prca.200800020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
28 Findeisen P, Zapatka M, Peccerella T, Matzk H, Neumaier M, Schadendorf D, Ugurel S. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol. 2009;27:2199-2208. [PMID: 19307507 DOI: 10.1200/jco.2008.18.0554] [Cited by in Crossref: 79] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
29 Seliger B, Dressler SP, Lichtenfels R, Kellner R. Candidate biomarkers in renal cell carcinoma. Proteomics 2007;7:4601-12. [DOI: 10.1002/pmic.200700415] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
30 Tammen H, Peck A, Budde P, Zucht H. Peptidomics analysis of human blood specimens for biomarker discovery. Expert Review of Molecular Diagnostics 2014;7:605-13. [DOI: 10.1586/14737159.7.5.605] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]